Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

microRNA-based method for treating malignant pleural mesothelioma

A pleural, malignant technology, applied in the fields of molecular biology and cancer, can solve the problems of ineffective delivery, poor effect of microRNA mimics, poor activity, etc., and achieve remarkable results

Inactive Publication Date: 2018-08-21
范兴龙
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] In addition, although relatively easy to use in vitro, microRNA mimics are often ineffective in terms of in vivo efficacy due to two issues: first, poor activity (including low RISC binding and off-target effects), and second, inefficient delivery (compared to Stability and specific / selective distribution to site of action)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • microRNA-based method for treating malignant pleural mesothelioma
  • microRNA-based method for treating malignant pleural mesothelioma
  • microRNA-based method for treating malignant pleural mesothelioma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] A microRNA-based method for treating malignant pleural mesothelioma, comprising an antibody or fragment thereof binding to ganglioside GM2 as an active ingredient and a microRNA mimic comprising a mature sequence and a follower chain, the mature sequence comprising a sequence selected from the group consisting of SEQID NOS: 11-14, the follower chain comprising a sequence selected from the group consisting of SEQID NOS: 15-18, and the follower chain is inactivated by chemical modification, the antibody is recombinant An antibody, and wherein the antibody is an antibody comprising heavy chain complementarity determining regions 1 to 3 respectively having amino acid sequences of SEQ ID NO: 1 to 3 and light chain CDR1 to 3 having respectively amino acid sequences of SEQ ID NO: 4 to 6, said The antibody is one selected from the following: an antibody comprising an H-chain variable region having an amino acid sequence of SEQ ID NO: 7 and an L-chain variable region having an am...

Embodiment 2

[0029] A microRNA-based method of treating malignant pleural mesothelioma, the microRNA mimics may be administered to a subject by any means suitable for delivering these compounds to cancer cells in the subject, for example, the microRNA mimics may be administered by A method of transfecting cells suitable for a subject, administering with said mimetic, or with a nucleic acid comprising a sequence encoding these compounds, said microRNA mimetic comprising simultaneous or sequential co-administration of an adjuvant anti-cancer therapy, the The adjuvant includes at least one combined drug, and the adjuvant is an ERβ agonist and a platinum-containing anticancer drug. At the same time, the ERβ agonist and the platinum-containing anticancer drug can be combined with other agents suitable for the treatment of mesothelioma (such as culture Metrexed) (such as Figure 4 shown) are used in combination, the individual components of this combination may be administered separately at diff...

Embodiment 3

[0031] In the treatment of malignant pleural mesothelioma based on microRNA, other treatment methods can be added for adjuvant treatment, such as:

[0032] Surgical treatment of tumors: Surgical treatment of tumors is to remove tumor lesions through surgery to achieve the purpose of treatment. Surgical resection of tumors is not limited by biological characteristics. Most tumors that have not spread can often be cured by surgery. At the same time, surgery can understand The correct location of the tumor and the correct stage can guide further treatment. Surgery is the first choice and effective treatment method for most patients with early and mid-stage malignant tumors, but it also has its own shortcomings, such as causing new symptoms to patients. trauma; part of the normal tissue resection may produce some dysfunction or sequelae, etc.; when the tumor infiltrates too much or invades important organs and large blood vessels, it is often impossible to perform surgery, or surge...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a microRNA-based method for treating malignant pleural mesothelioma, wherein the traditional Chinese medicine raw materials comprise, by mass, an active component and a microRNA simulant, the active component is a ganglioside GM2 conjugated antibody or a fragment thereof, the microRNA simulant contains a mature sequence and a lagging strand, the antibody is a recombinant antibody, and the recombinant antibody is one selected from a chimeric antibody, a humanized antibody and a human antibody. According to the present invention, the microRNA-based method can be combinedwith radiotherapy, thermotherapy and photodynamics; and the ganglioside GM2 conjugated antibody or the fragment thereof is used as the active component, the microRNA-based microRNA stimulant is used as the main treatment means, and surgery therapy, chemotherapy, radiotherapy, biological therapy, thermotherapy and photodynamic therapy are used as the auxiliary treatment ways, such that the effectsare significant by combining various treatments.

Description

technical field [0001] The invention belongs to the fields of molecular biology and cancer, and in particular relates to a microRNA-based method for treating malignant pleural mesothelioma. Background technique [0002] Malignant pleural mesothelioma is almost always a fatal cancer for which few treatments are available. Novel therapeutics are urgently needed, and dysregulated microRNA expression provides a source of novel therapeutic targets. MicroRNAs (miRNAs) are a class of small non-coding RNAs discovered in recent years with a length of 18-24 nucleotides. It mainly degrades target gene mRNA or inhibits its translation through complete or incomplete pairing with the target gene 3'UTR, thereby participating in the regulation of individual development, cell apoptosis, proliferation and differentiation and other life activities. Experimental evidence shows that miRNAs can act as tumor suppressor genes or oncogenes, and are closely related to the formation of tumors, where...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61K41/00A61K51/00A61P35/00A61K31/519A61K33/24A61K31/7105
CPCA61K39/395A61K31/519A61K31/7105A61K33/24A61K41/0052A61K41/0057A61K51/00A61K2300/00
Inventor 范兴龙刘玉霞范徳开
Owner 范兴龙
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com